We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Collaboration to Advance Molecular Imaging Technology

By HospiMedica staff writers
Posted on 20 Oct 2003
A collaboration to develop a cost-effective, readily accessible molecular imaging technology that can help more clinics and hospitals diagnose cancer has been announced by Philips Medical Systems (Best, The Netherlands) and CellPoint, L.L.C. (Englewood, CO, USA).

The collaboration will combine Cellpoint's novel diagnostic imaging agent and the nuclear medicine camera of Philips to make functional imaging readily available. The agreement will utilize CellPoint's ethylenedicysteine drug conjugate technology (EC technology), a delivery system that links tissue-specific ligands (hormones, proteins, peptides) or pharmaceutical compounds to radioisotopes for cancer diagnosis and treatment. Using clinical trial data, Philips will further develop and refine imaging techniques for SKYlight, its gantry-free nuclear camera, to determine requirements for the highest possible image quality and quantitative information about patients' disease.

The companies will collaborate on CellPoint's first imaging agent, Tc-99m-EC-deoxyglucose. EC technology allows the deoxyglucose to be labeled with the radioisotope technetium-99m (Tc-99m). The agent will target tumors, while single positron emission computed tomography (SPECT) cameras will image them, including Philips' nuclear medicine cameras. Tumors absorb more glucose than surrounding tissue, so when a cancer patient is injected with this chemically linked agent, active tumors will absorb both the glucose and the radioisotope.

"Philips has outstanding SPECT technology, and we're thrilled to strategically align ourselves with them to help advance molecular imaging agents, enabling more facilities to conduct cancer screening,” said Greg Colip, CEO of CellPoint. The company obtained the worldwide license to EC technology from the University of Texas M.D. Anderson Cancer Center (Houston, USA).




Related Links:
CellPoint
Philips Medical
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Digital Radiography System (Ceiling Free)
Digix CF Series
New
Fetal Monitor
BT-380

Channels

Critical Care

view channel
Image: Protaryx Medical’s Transseptal Puncture Device is a next-generation solution designed to deliver safe, efficient, and reproducible left-atrial entry to support contemporary therapies (photo courtesy of Protaryx Medical)

FDA-Cleared Transseptal Access Device Enables Site-Specific Left Atrial Puncture

Transseptal puncture is essential for gaining left atrial access during structural heart and electrophysiology procedures, yet it can be technically demanding and time-consuming. Suboptimal puncture site... Read more

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more